JAZZ News and Press, Jazz Pharmaceuticals plc From 05/16/19

Data to be presented underscore commitment to developing life-changing medicines in hematology/oncology for people with limited or no treatment options DUBLIN , May 16, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that it will present data from a...

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to stay informed about what companies are leading the industry. Pharma ETFs are key for investors who want to trade in a set of assets instead of individual companies. For novic...

The following slide deck was published by Jazz Pharmaceuticals plc in conjunction with this Read more ...

DUBLIN , May 9, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that 14 abstracts sponsored by Jazz Pharmaceuticals and one abstract from an investigator-sponsored trial will be presented at the 33 rd Annual Meeting of the Associated Professional Sleep S...

Jazz Pharmaceuticals, Inc. (JAZZ) Q1 2019 Results Earnings Conference Call May 7, 2019, 04:30 PM ET Company Participants Katherine Littrell - Head of Investor Relations Bruce Cozadd - Chairman and Chief Executive Officer Matthew Young - Executive Vice President and Chief Financia...

Jazz Pharmaceuticals plc (NASDAQ: JAZZ ) Q1 results ($M): Revenues: 508.2 (+14.3%); Xyrem sales: 368.3 (+16.3%). More news on: Jazz Pharmaceuticals plc, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...

The following slide deck was published by Jazz Pharmaceuticals plc in conjunction with their 2019 Q1 earnings Read more ...

Jazz Pharmaceuticals (NASDAQ: JAZZ ): Q1 Non-GAAP EPS of $3.67 beats by $0.51 ; GAAP EPS of $1.47 misses by $0.12 . Revenue of $508.2M (+14.3% Y/Y) beats by $41.65M . Press Release More news on: Jazz Pharmaceuticals plc, Earnings news and commentary, Healthcare stocks news,

DUBLIN , May 7, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2019 and reaffirmed 2019 financial guidance. "In the first quarter of 2019, we delivered strong top- and bottom-line growth and continued our effort...

Jazz Pharmaceuticals (NASDAQ: JAZZ ) is scheduled to announce Q1 earnings results on Tuesday, May 7th, after market close. The consensus EPS Estimate is $3.16 (+6.0% Y/Y) and the consensus Revenue Estimate is $466.55M (+4.9% Y/Y). Over the last 2 years, jazz has beaten EPS estimates ...